Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors

about

Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors

Item

http://www.wikidata.org/entity/Q59129702

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@en

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@nl

type

Item

label

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@en

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@nl

prefLabel

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@en

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@nl

P1476

Discovery of novel quinazoline ...... potent EGFR kinase inhibitors

@en

P2093

Bingbing Zhao

http://www.w3.org/2001/XMLSchema#string

Caolin Wang

http://www.w3.org/2001/XMLSchema#string

Luogen Lai

http://www.w3.org/2001/XMLSchema#string

Pengwu Zheng

http://www.w3.org/2001/XMLSchema#string

Qi Yang

http://www.w3.org/2001/XMLSchema#string

Wufu Zhu

http://www.w3.org/2001/XMLSchema#string

Yuanbiao Tu

http://www.w3.org/2001/XMLSchema#string

Zunhua Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Epidermal growth factor receptor mutations in lung cancer

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.

Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.

Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery.

Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.

P304

462-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CSBJ.2018.10.016

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30455856

http://www.w3.org/2001/XMLSchema#string

P932

6232652

http://www.w3.org/2001/XMLSchema#string